DIPRIVAN Emulsion for injection or infusion Ref.[8033] Active ingredients: Propofol

Source: Health Products Regulatory Authority (IE)  Revision Year: 2025  Publisher: Aspen Pharma Trading Limited, 3016 Lake Drive, Citywest Business Campus, Dublin 24, Ireland

Therapeutic indications

Diprivan is a short-acting intravenous general anaesthetic for:

  • Induction and maintenance of general anaesthesia in adults and children over one month of age.
  • Sedation for diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia in adults and children over one month of age.
  • Sedation of ventilated patients over 16 years of age in the intensive care unit.

Diprivan may be administered by a Diprifusor TCI system for induction and maintenance of general anaesthesia and conscious sedation for surgical and diagnostic procedures in adults only. Administration of Diprivan by a Diprifusor TCI system is not recommended for any indication in children or adolescents under 16 years old. Administration of Diprivan by a Diprifusor TCI system is not recommended for intensive care sedation.

Posology and method of administration

Posology

Supplementary analgesic agents are generally required in addition to Diprivan. For specific guidelines relating to the administration of Diprivan using the Diprifusor target controlled infusion (TCI) system, which incorporates Diprifusor TCI software, see section E. Such use is restricted to induction and maintenance of anaesthesia and conscious sedation for surgical and diagnostic procedures in adults. The Diprifusor TCI system is not recommended for use in ICU sedation, or in children or adolescents under 16 years old.

The glass pre‑filled syringe (PFS) has a lower frictional resistance than plastic disposable syringes and operates more easily. Therefore, if Diprivan is administered using a hand held pre‑filled syringe, the line between the syringe and the patient must not be left open if unattended.

A) Adults

Induction of General Anaesthesia

Diprivan 1% may be used to induce anaesthesia by slow bolus injection or infusion.

In unpremedicated and premedicated patients, it is recommended that Diprivan should be titrated (approximately 40 mg every 10 seconds in an average healthy adult by bolus injection or infusion) against the response of the patient until the clinical signs show the onset of anaesthesia. Most adult patients aged less than about 55 years are likely to require 1.5 to 2.5 mg/kg of Diprivan. The total dose required can be reduced by lower rates of administration (20–50 mg/min). Over this age, the requirement will generally be less. In patients of ASA grades 3 and 4, lower rates of administration should be used (approximately 20 mg every 10 seconds).

Maintenance of General Anaesthesia

Anaesthesia can be maintained by administering Diprivan either by continuous infusion or by repeat bolus injections to maintain the depth of anaesthesia required.

Continuous Infusion: Diprivan 1% may be used. The required rate of administration varies considerably between patients but rates in the region of 4 to 12 mg/kg/h usually maintain satisfactory anaesthesia.

Repeat Bolus Injection: If a technique involving repeat bolus injection is used, increments of 25 mg to 50 mg may be used according to clinical need.

Sedation of Ventilated Patient in the Intensive Care Unit

For sedation during intensive care it is advised that Diprivan should be administered by continuous infusion. The infusion rate should be determined by the desired depth of sedation. In most patients sufficient sedation can be obtained with a dosage of 0.3–4 mg/kg/h of Diprivan (see section 4.4). Diprivan is not indicated for sedation in intensive care of patients of 16 years of age or younger (see section 4.3). Administration of Diprivan by Diprifusor TCI system is not advised for sedation in the intensive care unit.

Conscious Sedation for Surgical and Diagnostic Procedures

To provide sedation for surgical and diagnostic procedures rates of administration should be individualised and titrated to clinical response.

Most patients will require 0.5 to 1 mg/kg over 1 to 5 minutes to initiate sedation.

Maintenance of sedation may be accomplished by titrating Diprivan infusion to the desired level of sedation – most patients will require 1.5 to 4.5 mg/kg/h. In addition to the infusion, bolus administration of 10 to 20 mg may be used if a rapid increase in the depth of sedation is required. In patients of ASA grades 3 and 4 the rate of administration and dosage may need to be reduced.

B) Elderly patients

In older people the dose requirement for induction of anaesthesia with Diprivan is reduced. The reduction should take account of the physical status and age of the patient. The reduced dose should be given at a slower rate and titrated against the response. Where Diprivan is used for maintenance of anaesthesia or sedation the rate of infusion or 'target concentration' should also be reduced. Patients of ASA grades 3 and 4 will require further reductions in dose and dose rate. Rapid bolus administration (single or repeated) should not be used in older people as this may lead to cardiorespiratory depression.

C) Paediatric population

Diprivan is not recommended for use in children less than one month of age.

Administration of Diprivan by a Diprifusor TCI system is not recommended for any indication in children.

Induction of General Anaesthesia

For induction of anaesthesia in children over 1 month of age, Diprivan 1% should be titrated slowly until clinical signs show the onset of anaesthesia. The dose should be adjusted according to age and/or body weight. Most patients over 8 years of age require approximately 2.5 mg/kg body weight of Diprivan 1% for induction of anaesthesia. In younger children, especially between the age of 1 month and 3 years, dose requirements may be higher (2.5–4 mg/kg body weight).

Maintenance of General Anaesthesia

Anaesthesia can be maintained by administering Diprivan by infusion or repeated bolus injection to maintain the depth of anaesthesia required. The required rate of administration varies considerably between patients but rates in the region of 9–15 mg/kg/h usually achieve satisfactory anaesthesia. In younger children, especially between the age of 1 month and 3 years, dose requirements may be higher.

For ASA 3 and 4 patients lower doses are recommended (see also Section 4.4).

Conscious Sedation for Surgical and Diagnostic Procedures

Diprivan 1% is not recommended for surgical and diagnostic procedures in children aged less than 1 month.

In children over 1 month of age, doses and administration rates should be adjusted according to the required depth of sedation and the clinical response. Most paediatric patients require 1–2 mg/kg body weight of Diprivan 1% for onset of sedation. Maintenance of sedation may be accomplished by titrating Diprivan 1% infusion to the desired level of sedation. Most patients require 1.5–9 mg/kg/h Diprivan 1%. The infusion may be supplemented by bolus administration of up to 1 mg/kg body weight if a rapid increase of depth of sedation is required.

In ASA 3 and 4 patients lower doses may be required.

D) Administration

Method of administration

Diprivan can be used for infusion undiluted from plastic syringes or glass infusion bottles or Diprivan pre‑filled syringes. When Diprivan is used undiluted to maintain anaesthesia, it is recommended that equipment such as syringe pumps or volumetric infusion pumps should always be used to control infusion rates.

Diprivan 1% may also be used diluted with 5% Dextrose Intravenous Infusion only, in PVC infusion bags or glass infusion bottles. Dilutions, which must not exceed 1 in 5, should be prepared aseptically immediately before administration. The mixture is stable for up to 6 hours.

The dilution may be used with a variety of infusion control techniques but a giving set used alone will not avoid the risk of accidental, uncontrolled infusion of large volumes of diluted Diprivan. A burette, drop counter or volumetric pump must be included in the infusion line. The risk of uncontrolled infusion must be taken into account when deciding the maximum amount of dilution in the burette.

Diprivan may be administered by a Y‑piece close to the injection site, into infusions of Dextrose 5% Intravenous Infusion, Sodium Chloride 0.9% Intravenous Infusion or Dextrose 4% with Sodium Chloride 0.18% Intravenous Infusion.

In order to reduce pain on initial injection, Diprivan 1% used for induction may be mixed with Lidocaine Injection in a plastic syringe in the ratio of 20 parts Diprivan 1% with up to one part of 0.5 or 1% Lidocaine Injection immediately prior to administration.

Diprivan 1% may be premixed with alfentanil injection containing 500 micrograms/ml alfentanil ('Rapifen'; Janssen Pharmaceuticals Ltd) in the ratio of 20:1 to 50:1 v/v. Mixtures should be prepared using sterile technique and used within 6 hours of preparation at room temperature and under normal lighting conditions.

The neuromuscular blocking agents atracurium and mivacurium should not be given through the same IV line as Diprivan without prior flushing.

Dilution and Co‑administration of Diprivan with other Drugs or Infusion Fluids:

Co-administration
Technique
Additive or DiluentPreparationPrecautions
Pre‑mixingDextrose 5% Intravenous InfusionMix 1 part of
Diprivan 1%
with up to 4
parts of
Dextrose 5%
Intravenous
Infusion in
either PVC
infusion bags
or glass
infusion
bottles. When
diluted in PVC
bags it is
recommended
that the bag
should be full
and that the
dilution be
prepared by
withdrawing a
volume of
infusion fluid
and replacing
it with an
equal volume
of Diprivan 1%.
Prepare
aseptically
immediately
before
administration.
The mixture is
stable for up
to 6 hours.
 Lidocaine Hydrochloride Injection
(0.5% or 1% without preservatives)
Mix 20 parts of
Diprivan 1%
with up to
1 part of either
0.5% or 1%
Lidocaine
Hydrochloride
Injection.
Prepare
mixture
aseptically
immediately
prior to
administration.
Use for
induction only.
 Alfentanil injection (500 micrograms/ml)Mix Diprivan
1% with
alfentanil
injection in a
ratio of 20:1 to
50:1 v/v.
Prepare
mixture
aseptically; use
within 6 hours
of preparation.
Co-administration
via a
Y‑piece
connector
Dextrose 5% Intravenous InfusionCo‑administer
via a Y‑piece
connector.
Place the
Y‑piece
connector
close to the
injection site.
 Sodium Chloride 0.9% Intravenous InfusionAs aboveAs above
 Dextrose 4% with Sodium Chloride 0.18%
Intravenous Infusion
As aboveAs above

E) Target Controlled Infusion – Administration of Diprivan by Diprifusor TCI System in Adults

Diprivan may be administered by TCI with the Diprifusor TCI system incorporating Diprifusor TCI software. This system will operate only on recognition of electronically tagged pre-filled syringes containing Diprivan 1%. The Diprifusor TCI system will automatically adjust the infusion rate to achieve the concentration of Diprivan selected by the operator. Users must be familiar with the infusion pump user manual and with the administration of Diprivan by TCI and with the correct use of the syringe identification system.

The Diprifusor TCI system can provide two modes of target controlled infusion: target blood concentration and target effect-site (brain) concentration. Earlier models provide only the target blood concentration mode.

Administration of Diprivan by a Diprifusor TCI system is restricted to adults for the induction and maintenance of general anaesthesia and conscious sedation for surgical and diagnostic procedures. It is not recommended for use in ICU sedation or in children or adolescents under 16 years old.

The system allows control of induction and depth of anaesthesia or conscious sedation by setting and adjusting target (predicted) blood or effect-site concentrations of propofol. Use of the target effect-site concentration mode achieves a more rapid induction of sedation or anaesthesia than use of the target blood concentration mode.

The pharmacokinetic model in Diprifusor TCI system assumes that the initial target concentrations in the patient are zero. Therefore, in patients who have recently received prior propofol, there may be a need to select a lower initial target concentration when commencing Diprifusor TCI. Similarly, the immediate recommencement of Diprifusor TCI is not recommended if the pump has been switched off; if this has occurred, the Diprifusor TCI system indicates that it has been switched off by requiring re‑entry/confirmation of patient data.

Guidance on propofol target concentrations is given below. In view of interpatient variability in propofol pharmacokinetics and pharmacodynamics, in both premedicated and unpremedicated patients the target propofol concentration should be titrated against the response of the patient in order to achieve the depth of anaesthesia or conscious sedation required.

In adult patients under 55 years of age, anaesthesia can usually be induced with target blood propofol concentrations in the region of 4 to 8 micrograms/ml or target effect-site concentrations of 2.5 to 4 micrograms/ml. An initial target blood concentration of 4 micrograms/ml or target effect-site concentration of 2.5 micrograms/ml is recommended in premedicated patients and in unpremedicated patients an initial target blood concentration of 6 micrograms/ml or target effect-site concentration of 4 micrograms/ml is advised. Induction time with target blood concentrations is generally within the range of 60–120 seconds. Higher target blood concentrations will allow more rapid induction of anaesthesia but may be associated with more pronounced haemodynamic and respiratory depression. When using target effect-site concentrations the use of higher targets to achieve more rapid induction of anaesthesia is not necessary and not recommended.

Lower initial target concentrations should be used in patients over the age of about 55 years and in patients of ASA grades 3 and 4 (use of effect-site mode in patients of ASA grade 4 is not recommended). For the effect-site mode an initial target of 0.5 to 1 micrograms/ml should be used. For both target concentration modes, the target can then be increased in steps of 0.5 to 1 microgram/ml at intervals of 1 minute to achieve a gradual induction of anaesthesia.

Supplementary analgesia will generally be required and the extent to which target concentrations for maintenance of anaesthesia can be reduced will be influenced by the amount of concomitant analgesia administered. Target propofol blood concentrations in the region of 3 to 6 micrograms/ml and target effect-site concentrations of 2.5 to 4 micrograms/ml usually induced and maintain satisfactory anaesthesia. In the absence of supplementary analgesia, higher effect-site targets of 5 to 6 micrograms/ml may be required to facilitate laryngoscopy or to abolish responses to painful stimuli.

For both target concentration modes, the predicted propofol concentration (blood or effect-site) on waking is generally in the region of 1 to 2 micrograms/ml and will be influenced by the amount of analgesia given during maintenance. When target concentrations are reduced, the Diprifusor transiently stops the infusion to allow concentrations to fall and achieve a new target more quickly.

Conscious Sedation for Surgical and Diagnostic Procedures

The target concentration setting should be titrated against the response of the patient to achieve the depth of conscious sedation required.

An initial target blood propofol concentration in the range of 0.5 to 2.5 micrograms/ml will generally be required. Initial target blood concentrations towards the upper end of the recommended range will allow more rapid induction of conscious sedation.

In older people and in patients of ASA grades 3 and 4, initial target blood concentrations towards the lower end of the range should be used.

In young, healthy patients, an effect-site target of 1.5 to 2 micrograms/ml generally achieves satisfactory sedation, which is achieved more rapidly than when the target blood concentration control mode is used. When using target effect-site concentrations the use of higher targets to achieve more rapid induction of sedation is not necessary and not recommended. There is insufficient evidence to recommend use of effect-site mode for conscious sedation in older people or patients of ASA grades 3 or 4.

Routine oxygen supplementation should be provided.

Overdose

Accidental overdosage is likely to cause cardiorespiratory depression. Respiratory depression should be treated by artificial ventilation with oxygen. Cardiovascular depression would require lowering of the patient's head and, if severe, use of plasma expanders and pressor agents.

Shelf life

Shelf life of the product as packaged for sale:

2 years (20 ml)

3 years (50 ml)

Special precautions for storage

Do not store above 25°C. Do not freeze.

For storage precautions for diluted product, see section 6.3 Shelf Life.

Nature and contents of container

Type I glass pre-filled syringes containing 20 ml or 50 ml.

Not all pack sizes may be marketed.

Special precautions for disposal and other handling

For more detailed administration instructions for Diprivan and mixtures of Diprivan, please see section 4.2 Posology and Method of Administration.

In‑use precautions: Containers should be shaken before use. Any portion of the contents remaining after use should be discarded.

When the pre‑filled syringe presentation is used in a syringe pump appropriate compatibility should be ensured. In particular, the pump should be designed to prevent siphoning and should have an occlusion alarm set no greater than 1000 mm Hg. If using a programmable or equivalent pump that offers options for use of different syringes then choose only the B‑D 50/60 ml PLASTIPAK setting when using the Diprivan pre‑filled syringe.

Asepsis for Diprivan and infusion equipment must be maintained (see Section 4.4 Warnings and precautions for use).

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈